cryptomobilegamesios| Shengnuo Pharmaceutical Dai Xiaochang resigns as chief strategy officer: continues to serve as executive director and serves as drug development consultant

News summary

Shengnuo Pharmaceuticals-B(02257cryptomobilegamesios.HK) Chief Strategy Officer Dai Xiaochang resigned on May 17 due to private reasonscryptomobilegamesios, but remains as an executive director and is appointed as a senior consultant for the group's drug development and commercialization.

Newsletter text

[Dai Xiaochang, chief strategy officer of Shengnuo Pharmaceutical, leaves office] On May 17, Shengnuo Pharmaceutical (stock code: 02257cryptomobilegamesios.HK) issued an announcement stating that Dai Xiaochang decided to resign as chief strategy officer due to personal reasons, and the decision will take effect from the day of the announcement.

Dai Xiaochang continued to serve as executive director and agreed to serve as a member of the group's drug development and commercializationcryptomobilegamesiossenior consultant. This move is regarded as another important measure by the company in strategic adjustment and talent layout.